Lipoprotein(a): The Hidden Genetic Heart Risk Finally Becoming Treatable in 2026

In 1963, a Norwegian geneticist named Kåre Berg, working at the University of Oslo, identified a strange variant of low-density lipoprotein in human plasma. He named it lipoprotein(a). For the next six decades, the discovery sat at the edges of cardiovascular medicine, known to specialists, ignored by everyone else. That changed in 2026. Four pivotal Phase 3 trials are now reading out or approaching readout for therapies that directly lower Lp(a), an inherited risk factor that roughly one in five people on the planet carries in dangerous concentrations. If any of these trials succeed, cardiology will enter a new era in which the single largest genetic driver of heart attack and stroke becomes treatable for the first time.

Presented By Our Partners

This is the story of how Lp(a) went from a forgotten lab curiosity to the most talked about molecule in cardiovascular prevention, and what the next eighteen months of clinical data will mean for patients, clinicians, and the larger practice of preventive medicine.

What Lipoprotein(a) Actually Is

Lp(a) is structurally similar to the familiar low-density lipoprotein particle that carries cholesterol through the bloodstream, with one critical addition. A second protein, called apolipoprotein(a) or apo(a), wraps around the LDL core and attaches to apolipoprotein B100 by a disulfide bond. The apo(a) component is the distinguishing feature. It has no known beneficial function, varies dramatically in size between individuals, and confers risk through mechanisms that scientists are still piecing together.

Research published in the Journal of the American College of Cardiology and led by Sotirios Tsimikas at UC San Diego has demonstrated three converging mechanisms by which Lp(a) drives cardiovascular disease. First, the LDL-like core delivers cholesterol directly into arterial walls, contributing to atherosclerotic plaque the same way ordinary LDL does. Second, the apo(a) tail carries oxidized phospholipids, the most pro-inflammatory lipids in human biology, which accelerate plaque growth and destabilization. Third, apo(a) structurally resembles plasminogen, the enzyme that dissolves blood clots, and interferes with the body’s natural clot-dissolving machinery, creating a prothrombotic state.

The result is a particle that is simultaneously atherogenic, inflammatory, and thrombogenic. In a 2020 meta-analysis published in Circulation drawing on more than 460,000 individuals, researchers found that Lp(a) concentrations above 150 nmol/L roughly doubled the risk of coronary heart disease independent of LDL cholesterol, blood pressure, smoking status, and every other traditional risk factor.

The Genetics No Diet Can Fix

Unlike LDL cholesterol, which responds dramatically to statins, diet, and exercise, Lp(a) levels are roughly 90 percent genetically determined. The LPA gene on chromosome 6 contains a variable number of copies of a sequence called kringle IV type 2. People who inherit fewer copies produce smaller, more numerous Lp(a) particles in higher plasma concentrations. The Copenhagen General Population Study, a landmark Danish cohort analyzed by Børge Nordestgaard and colleagues, established that these genetic variants correspond one-to-one with cardiovascular risk.

Mendelian randomization studies, which use genetic variants as natural experiments to establish causation rather than correlation, have been definitive. Individuals who inherit LPA variants producing lifelong elevated Lp(a) have markedly higher rates of myocardial infarction, ischemic stroke, calcific aortic valve stenosis, and heart failure. The relationship is dose dependent and persists across ethnic groups, though mean Lp(a) levels vary significantly by ancestry. Populations of African descent generally have higher median Lp(a) levels than European or East Asian populations, though whether this translates equally into clinical risk is still being clarified.

Roughly 20 to 25 percent of the global population carries Lp(a) levels above the threshold at which cardiovascular risk begins to climb meaningfully. In the United States alone, that means more than 60 million adults carry an elevated genetic risk factor for heart disease that, until now, has had no targeted treatment.

Why Sixty Years Passed Without a Drug

The gap between discovery and therapy reflects several realities of drug development. Statins, which dominated the cardiovascular prevention landscape from the 1990s through the 2010s, do not meaningfully lower Lp(a). Some patients see modest reductions, others see small increases, and the net population effect is close to zero. Niacin lowers Lp(a) by about 20 to 30 percent but failed to improve cardiovascular outcomes in the AIM-HIGH and HPS2-THRIVE trials, and has largely been abandoned. PCSK9 inhibitors such as evolocumab and alirocumab lower Lp(a) by roughly 25 percent, but subgroup analyses from the FOURIER and ODYSSEY Outcomes trials suggested the benefit attributable to Lp(a) reduction alone was modest.

The real obstacle was that Lp(a) production is unusual. It is synthesized almost exclusively in the liver, and its assembly requires the LPA gene to produce apo(a) at levels largely determined by genetic copy number. To substantially reduce Lp(a), you need to shut down hepatic apo(a) synthesis directly. That capability did not exist until antisense oligonucleotides and small interfering RNA technologies matured in the 2010s.

The Four Trials That Will Define the Field

The 2020s have produced an unprecedented pipeline of genetically targeted Lp(a) therapies, each using different molecular strategies to silence apo(a) production in the liver. Four Phase 3 trials are now the focus of cardiology’s attention.

Pelacarsen (Novartis)

Pelacarsen, licensed from Ionis Pharmaceuticals, is an antisense oligonucleotide conjugated to a GalNAc sugar that targets hepatocytes specifically. Given by monthly subcutaneous injection, pelacarsen binds to the APO(a) messenger RNA and prevents its translation into protein. In Phase 2 results published in the New England Journal of Medicine by Tsimikas and colleagues, pelacarsen lowered Lp(a) by up to 80 percent at the highest dose.

The pivotal Phase 3 trial, HORIZON, enrolled 8,323 patients with established cardiovascular disease and Lp(a) levels above 70 mg/dL. Topline results, which industry watchers expect to emerge in mid to late 2026, will determine whether the observed reduction in Lp(a) translates into a reduction in major adverse cardiovascular events. If positive, pelacarsen would likely become the first Lp(a) lowering therapy approved by the FDA and the European Medicines Agency.

Olpasiran (Amgen)

Olpasiran takes a different approach, using small interfering RNA rather than antisense technology. It is administered subcutaneously every twelve weeks, a considerable convenience advantage over monthly dosing. In the OCEAN(a)-DOSE Phase 2 trial published in the New England Journal of Medicine, olpasiran reduced Lp(a) by more than 95 percent at higher doses, with effects persisting for months after the final injection.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

The Phase 3 trial, OCEAN(a)-Outcomes, is enrolling approximately 6,000 patients with atherosclerotic cardiovascular disease and elevated Lp(a), with a primary endpoint of cardiovascular death, myocardial infarction, stroke, or urgent coronary revascularization. The trial is expected to continue through 2027, but interim safety and pharmacodynamic data have reinforced confidence in the approach.

Lepodisiran (Eli Lilly)

Lepodisiran is an even longer-acting small interfering RNA that may require dosing only once or twice per year. Phase 2 data published in JAMA showed durable Lp(a) reductions exceeding 90 percent following a single injection, with effects measurable a full year later. Lilly’s ACCLAIM-Lp(a) Phase 3 trial is enrolling patients and positions lepodisiran as the longest-interval option in the field, a profile that could transform adherence patterns in primary prevention.

Muvalaplin (Eli Lilly)

Alone among the leading candidates, muvalaplin is an oral small molecule rather than an injectable nucleic acid therapy. It works by a distinct mechanism, disrupting the assembly of apo(a) with apolipoprotein B100 rather than silencing apo(a) production. Early Phase 2 data published in JAMA by Stephen Nicholls and colleagues demonstrated Lp(a) reductions of up to 85 percent with a once-daily pill. An oral Lp(a) lowering agent would significantly broaden access and simplify combination with existing cardiovascular drug regimens. Larger outcomes trials are in planning.

Zerlasiran (Silence Therapeutics)

Zerlasiran, a small interfering RNA developed by Silence Therapeutics, reported Phase 2 results in JAMA in 2024 showing Lp(a) reductions of more than 80 percent with dosing every sixteen weeks. The company is advancing into Phase 3 planning and has signaled interest in exploring broader populations including primary prevention.

Testing: The Guideline Shift

The therapeutic pipeline has driven a parallel shift in screening recommendations. In 2024, the European Society of Cardiology and the European Atherosclerosis Society published updated consensus guidance recommending that every adult have Lp(a) measured at least once in their lifetime. The American Heart Association and the National Lipid Association have echoed this position, with the American College of Cardiology issuing a scientific statement authored by cardiologists including Christie Ballantyne and Erin Michos arguing that universal one-time screening is clinically and cost justified.

The logic is straightforward. Lp(a) is roughly 90 percent genetic, stable across adult life, and a single measurement provides lifetime risk stratification comparable to what a cholesterol test provides for a single year. Current laboratory standards report Lp(a) either in mg/dL or nmol/L, with the molar unit preferred because it is less affected by the variable particle size that confounds mass-based measurements. Most laboratories now offer standardized isoform-insensitive assays, and several reference laboratories including Quest Diagnostics, Labcorp, and Boston Heart Diagnostics report Lp(a) in nmol/L with clear cut points.

Clinically relevant thresholds are still being refined, but general consensus has coalesced around the following bands. Below 75 nmol/L, risk is considered low. Between 75 and 125 nmol/L, risk is moderately elevated. Above 125 nmol/L, risk is considered high, and above 250 nmol/L is associated with substantially elevated lifetime risk of coronary heart disease and aortic valve disease.

Aortic Stenosis: The Overlooked Lp(a) Disease

While most attention has focused on Lp(a) and coronary disease, a growing body of evidence points to Lp(a) as the strongest lipid driver of calcific aortic valve stenosis, a progressive disease in which the aortic valve calcifies and narrows until valve replacement becomes necessary. Research by George Thanassoulis and colleagues, published in the New England Journal of Medicine, demonstrated that LPA genetic variants independently predicted aortic valve calcification on CT imaging and clinical progression to aortic stenosis.

This matters because aortic stenosis is a growing cause of morbidity in older adults, its treatment requires surgical or transcatheter valve replacement, and there is currently no medical therapy that slows its progression. If Lp(a) lowering therapies prove effective in this domain, it would represent the first pharmacologic intervention for what has long been considered a purely mechanical disease. Substudies within the HORIZON and OCEAN(a)-Outcomes trials will provide preliminary signals, though dedicated aortic stenosis trials are likely to follow.

The Inflammation Question

One of the most scientifically intriguing aspects of Lp(a) biology is its relationship to inflammation. Research by Paul Ridker and colleagues at Brigham and Women’s Hospital, whose work on high-sensitivity C-reactive protein and the later CANTOS trial reshaped understanding of inflammatory cardiovascular risk, has suggested that Lp(a) may be part of the residual inflammatory risk that persists in patients well treated with statins.

A 2023 analysis published in the European Heart Journal found that patients with both elevated Lp(a) and elevated high-sensitivity CRP had substantially higher event rates than patients with either marker elevated in isolation. This synergy between atherogenic lipoproteins and inflammation is a central theme in modern cardiovascular biology, and if Lp(a) lowering therapies reduce events, part of the mechanism may involve lowering the inflammatory burden carried by oxidized phospholipids on the Lp(a) particle.

Open Questions and Reasons for Caution

The enthusiasm surrounding Lp(a) therapeutics is real, but clinicians and researchers have identified several open questions that the next two years of data must address.

First, how much Lp(a) reduction translates into how much clinical benefit is not yet clear. Mendelian randomization models suggest that meaningful event reduction may require absolute Lp(a) decreases of at least 65 mg/dL or 150 nmol/L, which means patients with modestly elevated Lp(a) may not benefit substantially while those with very high levels may see transformative risk reduction. Trial results will clarify this dose-response relationship.

Second, long-term safety of profound Lp(a) suppression remains unknown. Because Lp(a) has no known beneficial function in humans, the prior probability of significant harm is low, but some investigators have raised questions about effects on clotting or tissue repair that might emerge only with years of use. The trials now reading out will provide initial safety data over trial durations of three to five years, and post-marketing surveillance will extend that picture.

Third, cost and access will shape the real-world impact of these therapies. Nucleic acid therapies have historically been expensive, though pricing strategies vary. If approved drugs are priced similarly to PCSK9 inhibitors, uptake will depend heavily on payer policies and risk stratification approaches that identify the patients most likely to benefit.

Fourth, the appropriate population for treatment remains a subject of debate. Secondary prevention, meaning patients with established cardiovascular disease, represents the most likely initial indication. Primary prevention in asymptomatic individuals with high Lp(a), particularly those with family histories of premature coronary disease, is a larger and more complex population that regulators may or may not approve in the near term.

What This Means For You

If you have a family history of early heart attack, stroke, or sudden cardiac death, or if you have been diagnosed with coronary artery disease despite apparently well controlled LDL cholesterol and normal traditional risk factors, consider asking your clinician about Lp(a) testing. The test is a simple blood draw, widely available, and generally inexpensive. Most major insurance plans cover it. Because Lp(a) is stable across adult life, a single measurement is generally sufficient.

If your Lp(a) is elevated, several things are currently actionable even in advance of new therapies. Aggressive management of all other cardiovascular risk factors becomes even more important. That means rigorous LDL lowering, typically with statins and often with ezetimibe or PCSK9 inhibitors, to reduce the lifetime cholesterol burden carried into the arterial wall. It also means optimal blood pressure control, smoking cessation, regular aerobic exercise, a cardioprotective dietary pattern, and attention to sleep, stress, and metabolic health. Some clinicians also recommend daily low dose aspirin for individuals with very high Lp(a) and additional atherosclerotic risk, though the evidence here is evolving and the decision must be individualized.

First-degree relatives of individuals with elevated Lp(a) should also consider testing, because the trait is inherited in a codominant pattern and often runs in families with histories of early cardiovascular events. Identifying affected relatives allows preventive strategies to begin decades before clinical disease emerges.

For individuals with very high Lp(a) and established cardiovascular disease, the question of clinical trial participation is worth raising with a cardiologist. Trials such as HORIZON, OCEAN(a)-Outcomes, and ACCLAIM-Lp(a) are still enrolling at specialized centers and represent the most direct route to access investigational Lp(a) lowering therapy before regulatory approval.

Above all, do not assume that normal cholesterol means normal cardiovascular risk. Lp(a) is the most important cardiovascular risk factor most Americans have never heard of, and the next two years will likely bring the first therapies that can address it. Getting tested once is the first step toward participating in what cardiologists believe will be one of the most important preventive medicine shifts of the decade.

The Broader Picture

The rise of Lp(a) as a treatable target reflects a larger transformation underway in cardiovascular medicine. After four decades in which LDL cholesterol dominated thinking, the field is now opening to a more complex picture in which specific lipoprotein particles, inflammation markers, and genetic risk factors each contribute independently to cardiovascular events. Treatments are becoming more targeted, more genetically informed, and more personalized.

Lp(a) is also a case study in the power of nucleic acid therapeutics. Four of the five leading candidates use antisense oligonucleotides or small interfering RNA, technologies that were barely clinical a decade ago. Their success in this setting would accelerate adoption of similar approaches across lipidology, including therapies targeting apolipoprotein C3 for hypertriglyceridemia and angiopoietin-like 3 for combined dyslipidemias.

Sixty-three years after Kåre Berg first identified the strange lipoprotein variant in Oslo, the molecule he discovered is poised to move from academic interest to clinical reality. The trials reading out over the coming months will determine whether the promise holds. For the tens of millions of people who have lived their entire lives with an elevated genetic cardiovascular risk factor they could not modify, the answer matters more than almost any other question currently in play in preventive cardiology.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.